slide1 n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Arvind Raghavan, Ph.D., Vice President, Business Development PowerPoint Presentation
Download Presentation
Arvind Raghavan, Ph.D., Vice President, Business Development

Loading in 2 Seconds...

play fullscreen
1 / 28

Arvind Raghavan, Ph.D., Vice President, Business Development - PowerPoint PPT Presentation


  • 112 Views
  • Uploaded on

Innovative Nanostructures for Cancer Treatment. Arvind Raghavan, Ph.D., Vice President, Business Development. Who we are. Seed-stage biotech start-up University of MN technology Targeted therapeutic & diagnostic platform for a wide range of diseases.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Arvind Raghavan, Ph.D., Vice President, Business Development' - blenda


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

Innovative Nanostructures for Cancer Treatment

Arvind Raghavan, Ph.D., Vice President, Business Development

who we are
Who we are
  • Seed-stage biotech start-up
  • University of MN technology
  • Targeted therapeutic & diagnostic platform for a wide range of diseases.
  • Our mission is to improve human health by enabling individualized patient treatments for optimal patient outcomes.
the devastation of cancer
The Devastation of Cancer

241,200 Diagnosed

28,000 Deaths

290,000 Diagnosed

39,500 Deaths

Source: American Cancer Society, 2012

from the old to the new
From the old…to the new
  • Emphasis away from cytotoxic, non-specific chemotherapies to molecularly targeted, rationally designed drugs.
  • Shift to integrated cancer research and biomarker-driven adaptive and hypothesis testing clinical trials.
  • Treatment selection driven by understanding the genetics and biology of the cancer AND the patient.
from the old to the new1
From the old…to the new

Emphasis away from

cytotoxic, non-specific

chemotherapies to

molecularly targeted,

rationally designed

drugs.

from the old to the new2
From the old…to the new
  • Emphasis away from cytotoxic, non-specific chemotherapies to molecularly targeted, rationally designed drugs.
  • Shift to integrated cancer research and biomarker-driven adaptive and hypothesis testing clinical trials.
  • Treatment selection driven by understanding the genetics and biology of the cancer AND the patient.
from the old to the new3
From the old…to the new

Treatment selection driven by understanding

the genetics and biology of the cancer

AND the patient.

Arrays,

PCR,

PCR,

Arrays,

Chemo

+

Imaging

Imaging

+

mAb

Combo

mAbs

Combo

Chemo

targeted drugs
Targeted Drugs
  • By harnessing antibodies to deliver toxic payloads to cancer cells, while largely sparing healthy cells, the drugs are a step toward the “magic bullets” against cancer first envisioned by Paul Ehrlich, a German Nobel laureate, about 100 years ago.
  • Published: May 31, 2012

“I’m able to live a normal life,” said Saitowitz, 47, a mother of two young children. “I haven’t lost any of my hair.”

how targeted drugs work
How targeted drugs work
  • Antibody-drug conjugate

(Adcetris; Seattle Genetics)

http://www.adcetris.com/hcp/

tychon s technology
Tychon’s technology

Chemically Self-Assembled Nanostructures (CSANs)

Targeting Signal

+

Payload

Bio-functionalized Components

Dimerizer

Monomer

CSANs

Multimer

Dimer

tychon s technology1
Tychon’s technology

Chemically Self-Assembled Nanostructures (CSANs)

Targeting Signal

+

Payload

Bio-functionalized Components

Dimerizer

+

CSANs

Multimer

Dimer

tychon s technology2
Tychon’s technology

Chemically Self-Assembled Nanostructures (CSANs)

Specifically targets cancer cells, sparing normal cells

Targeting protein

Imaging agent

or Drug

tychon s technology4
Tychon’s technology

CSAN

Imaging agent

Identifies

cancer cell

tychon s technology5
Tychon’s technology

CSAN

Therapeutic agent

Enters

cancer cell

Kills

cancer cell

slide18

Product Pipeline

2013

2016

2015

2014

2018

2017

Prostate Imaging

$

$

$

Breast Imaging

$

$

Prostate Therapeutic

$

$

Breast Therapeutic

$

$

Pancreatic Therapeutic

$

slide19

. . . for cancer and autoimmune diseases that are engineered to hit two or more targets on cells instead of just one. In exchange for helping Merck create these so-called “bispecific” antibodies, Zymeworks is getting . . .

. . . the Zymeworks deal represents a chance for Merck to move into a hot area of protein drug engineering that biotech leaders like Genentech, Amgen, and Biogen Idec have been pursuing for years.

targeted drugs1
Targeted Drugs

“Pfizer is applying this ‘precision medicine’ strategy to diabetes, inflammation and other diseases aside from cancer, and aims by 2015 to have 50% of all its experimental drugs in human testing use the approach.”

- Mikael Dolsten, Pfizer's R&D chief

slide22

Individualized treatment

for improved quality of life.

our core team
OurCore Team

Brian R. White, Ph.D.

Head, R & D

Mark S. Robbins, Ph.D., J.D.

President & CEO

ArvindRaghavan,

Ph.D.

VP, Business Dev

Carston R. Wagner, Ph.D., CSO, Inventor,

U of MN

slide24

Accomplishments

Division Finalist in MN Cup.

Strong Business & Scientific Advisory Boards.

Ongoing partnership talks with five biotech companies.

Presented at 2012 Life Science Venture Summit.

Strong validation by Review Panel on SBIR proposals.

Grant award to Dr. Wagner from CPD.

slide25

Innovative Nanostructures for Cancer Treatment

Arvind Raghavan, Ph.D., Vice President, Business Development